These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11582587)

  • 1. Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma.
    Szende B; Romics I; Minik K; Szabó J; Torda I; Lovász S; Szomor L; Tóth L; Bély M; Kerényi T; Bartók K; Végh A
    Prostate; 2001 Oct; 49(2):93-100. PubMed ID: 11582587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of repeated biopsies in prognosis of prostate cancer].
    Romics I; Lovász S; Szabó J; Szomor L; Minik K; Bartók K; Kerényi T; Szende B
    Orv Hetil; 2002 Jul; 143(27):1619-23. PubMed ID: 12179998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis, mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma treated by androgen ablation.
    Szende B; Romics I; Torda I; Bély M; Szegedi Z; Lovász S
    Urol Int; 1999; 63(2):115-9. PubMed ID: 10592500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follow-up of prostate carcinoma patients treated with total androgen blockade by repeated map-biopsy.
    Szabo J; Bartok K; Keréni T; Vegh A; Romics I; Szende B
    Ann Urol (Paris); 2000 Aug; 34(4):236-9. PubMed ID: 10994142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical expression of bcl-2 and p53 oncoproteins: correlation with Ki67 proliferation index and prognostic histopathologic parameters in colorectal neoplasia.
    Saleh HA; Jackson H; Banerjee M
    Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):175-82. PubMed ID: 10981868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.
    Baretton GB; Klenk U; Diebold J; Schmeller N; Löhrs U
    Br J Cancer; 1999 May; 80(3-4):546-55. PubMed ID: 10408865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
    Augustin H; Freibauer C; Bayer L; Lunglmayr G; Tschurlovich F; Kuber W; Pummer K
    Prostate Cancer Prostatic Dis; 2006; 9(3):279-83. PubMed ID: 16702984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of p53 and bcl-2 in clinically localized prostate cancer before and after neo-adjuvant hormonal therapy.
    Cesinaro AM; Migaldi M; Ferrari G; Castagnetti G; Dotti A; De Gaetani C; Ferrari P; Trentini GP
    Oncol Res; 2000; 12(1):43-9. PubMed ID: 11061345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
    Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors in prostate cancer.
    Stattin P
    Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
    Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
    Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation.
    Matsuura H; Hayashi N; Kawamura J; Shiraishi T; Yatani R
    Eur Urol; 2000 Feb; 37(2):212-7. PubMed ID: 10705201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
    Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
    Laitinen S; Martikainen PM; Tammela TL; Visakorpi T
    Eur Urol; 2007 Sep; 52(3):725-32. PubMed ID: 17141945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors.
    Westin P; Stattin P; Damber JE; Bergh A
    Am J Pathol; 1995 Jun; 146(6):1368-75. PubMed ID: 7778676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis.
    D'Angelo E; Espinosa I; Ali R; Gilks CB; Rijn Mv; Lee CH; Prat J
    Gynecol Oncol; 2011 May; 121(2):328-33. PubMed ID: 21316747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.